The Team

**Principal Investigator**
MICHAEL L. SCHILSKY, MD
Yale University
New Haven, Connecticut

**Co-Investigator**
AFTAB ALA, MD, PHD
University of Surrey
Guildford, United Kingdom

**Co-Investigator**
REGINO GONZALEZ-PERALTA, MD
Florida Hospital
Orlando, Florida

**Co-Investigator**
SIHOUN HAHN, MD, PHD
Seattle Children’s Hospital
Seattle, Washington

**Co-Investigator**
SANJIV HARPAPAT, MD, PHD
Texas Children’s Hospital
Houston, Texas

**Co-Investigator**
KARL HEINZ-WEISS, MD
University of Heidelberg
Heidelberg, Germany

The Wilson Disease Association (WDA) is a 501(c)(3), all-volunteer organization striving to promote the well being of patients with Wilson Disease and their families and friends. We rely on donations to achieve our mission.

Wilson Disease Association
1732 1st Ave #20043
New York, NY 10128
(P) 414.961.0533, 866.961.0533, (F)414.962.3886
www.wilsonsdisease.org
What we have accomplished so far

DATA FROM YEARS 1 & 2 HAVE ALREADY YIELDED INFORMATION THAT WAS PREVIOUSLY UNKNOWN.

- Registry investigators have already published one scholarly article in the Journal of Psychosomatic Research. Major depressive disorder in patients with Wilson disease.
- Psychiatric assessments, to measure cognitive function, mood disorders, psychosis, personality changes and anxiety, will continue throughout the duration of the registry.
- Another study was conducted using data from the registry. The aim was to determine quality of life (QOL) in Wilson disease patients. Both mental health and physical health are affected in WD. It was found that patients with WD have worse mental health QOL scores than physical health QOL scores. QOL assessments will continue throughout the duration of the registry.
- These findings have been presented at professional meetings in the following countries: Denmark, Netherlands, United States, and United Kingdom in 2018 and 2019.
- Standard tests used to determine copper status are being collected and tested at a central laboratory run by Dr. Chris Harrington in the UK. These are serum ceruloplasmin and copper, which aid in determining “free copper.” Data from Years 1 and 2 have revealed that the calculation method of determining “free copper” is not a reliable indicator of copper status. To resolve these inconsistencies, Dr. Harrington has developed a test to measure “free copper” directly instead of using the calculation.

This illustrates the valuable progress that has been made in two short years with only a small cohort of patients at one center. Years 3 – 5, which will include a larger (+225 patients), a more diverse cohort of patients from other registry sites will yield information that is even more significant.

Patients enrolled in the registry will likely have been on more than one treatment, or a combination of treatments. It will be important to understand why therapies were changed over the course of patients’ treatment. Was it because of side effects or what was perceived to be treatment failure? To date we do not know exactly what constitutes treatment failure. It will be important to accurately define “treatment failure” in order to better design new clinical trials. It will also aid in learning how best to monitor patients who enter new clinical trials.

Moving forward

YEARS 3 – 5 WILL BE CRITICAL IN EVALUATING THE FOLLOWING STANDARD TESTS USED TO MONITOR FOR GOOD COPPER CONTROL.

- Neurologic Evaluation- All enrollees will be evaluated for neurological symptoms using a testing instrument called the Unified Wilson Disease Rating Scale (UWDRS). They will also be videotaped (with consent) to capture subtle differences that may not be picked up by the UWDRS.
- Copper Metabolism- As previously stated, ceruloplasmin and serum copper will continue to be tested and levels of “free copper” determined. 24 hour urine copper for copper content will also be analyzed. Urine zinc levels for patients on zinc treatment will also be measured.

AIM OF THE WPDR STUDY

By analyzing patient data and bio-specimens, the goal is to determine the ideal tests needed for diagnosis and the best monitoring practices. When compiled and analyzed by all study investigators, this information will reveal the proper use of current treatments and guide the development of future therapies. These data may also help to define ideal patient outcomes.

STUDY SITES

Study sites were chosen based on their expertise in adult and pediatric hepatology, neurology, psychology, nutrition as it relates to WD. Each site will have a study coordinator who will manage data, patient communications, and other important administrative tasks.

STUDY POPULATION

Patients will be adults and children who are seeking a diagnosis of WD, relatives of patients who need to be screened for WD; newly diagnosed patients who are in their initial stage of treatment; and those who have been on treatment for many years.

GENETIC- Molecular analysis of the ATP7B gene, will be done on each patient enrolled. The analyses will all be done by Dr. Shoun Hahn at Seattle Children’s Hospital in order to produce consistent results.

HEPATIC EVALUATION- Retrospective data on patients who have had a liver biopsy prior to entering the registry will be studied and categorized. New patients entering the registry who have not previously had a liver biopsy will have one and their results will be captured. Other laboratory testing, used to determine severity of liver disease, such as ALT, AST, albumin, INR, Bilirubin, GGT, alkaline phosphatase (ALP), creatinine and complete blood count (CBC) will be collected.

Cu

NEUROLOGIC EVALUATION- All enrollees will be evaluated for neurological symptoms using a testing instrument called the Unified Wilson Disease Rating Scale (UWDRS). They will also be videotaped (with consent) to capture subtle differences that may not be picked up by the UWDRS.

Cu

Patients enrolled in the registry will likely have been on more than one treatment, or a combination of treatments. It will be important to understand why therapies were changed over the course of patients’ treatment. Was it because of side effects or what was perceived to be treatment failure? To date we do not know exactly what constitutes treatment failure. It will be important to accurately define “treatment failure” in order to better design new clinical trials. It will also aid in learning how best to monitor patients who enter new clinical trials.

WHAT IS THE PATIENT REGISTRY & WHY IS IT SIGNIFICANT?
The Wilson Disease Patient Registry (WPDR) is a natural history study. Patients, medical practitioners and caregivers have waited years for this type of study in order to address unmet needs and unanswered questions about diagnosis, treatment, and monitoring. This type of study follows a group of people over a period of time who have a specific medical condition or disease. The study collects health information in order to better understand how the disease develops and how to treat it. The data collected will also be used to evaluate new therapies. In addition to data, the WPDR is also collecting and storing bio-specimens from each patient enrolled. All specimens are analyzed by the same laboratory in the UK to ensure consistency and stored in a central facility at Yale University.

What is the Patient Registry & why is it significant?

The Patient Registry creates a framework for advances in diagnosis, treatment and potential cures for the disease. Not only will the current generation of Wilson Disease patients benefit, but this registry will serve as a roadmap for future generations to come.

FAST FACTS

- It is the first of its kind in the world.
- Patients will be followed at various study sites in the U.S, the U.K and Europe.
- A multi-center registry enables us to collect data and bio-specimens (blood, urine) from a diverse population of patients, both adult and pediatric.
- It is a study that will require at least five years.
- It has a cost of approximately $33 million dollars as it is currently structured.
- We receive no government funding for it.

Creating our legacy

The Patient Registry creates a framework for advances in diagnosis, treatment and potential cures for the disease. Not only will the current generation of Wilson Disease patients benefit, but this registry will serve as a roadmap for future generations to come.

FUTURE DIRECTIONS

This illustrates the valuable progress that has been made in two short years with only a small cohort of patients at one center. Years 3 – 5, which will include a larger (+225 patients), a more diverse cohort of patients from other registry sites will yield information that is even more significant.

« Patients enrolled in the registry will likely have been on more than one treatment, or a combination of treatments. It will be important to understand why therapies were changed over the course of patients’ treatment. Was it because of side effects or what was perceived to be treatment failure? To date we do not know exactly what constitutes treatment failure. It will be important to accurately define “treatment failure” in order to better design new clinical trials. It will also aid in learning how best to monitor patients who enter new clinical trials.

(1) Shihlak Y, FDA Office of Orphan Products Development (OOPD), Orphan Product Clinical Trials Grants, submitted, 2016.«